Frank Vinluan is a Senior Biopharma Reporter for MedCity News. With a focus on the biopharmaceutical industry, Frank covers topics such as drug approvals, mergers and acquisitions, clinical trial data, and advancements in gene therapy and cell therapy. His articles provide insights into the latest developments and trends in the biopharma sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United States (National)
Not enough data
Not enough data
Frank Vinluan's coverage is heavily focused on the healthcare and pharmaceutical industry, with an emphasis on mergers and acquisitions, drug development, FDA approvals, and biotech. He frequently cites data in his articles, indicating a reliance on factual evidence.
Given his focus on M&A deals and drug developments within the healthcare sector, Frank may be interested in receiving pitches related to exclusive insights from industry experts or company executives involved in these transactions or new developments. Pitches emphasizing unique data-driven analyses or perspectives from key opinion leaders could also resonate well with him.
As there is no specific geographic focus mentioned for Frank's reporting, relevant news or expert analysis from any location within the global pharmaceutical and biotech industries would likely be of interest to him.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Frank Vinluan
Novartis is getting global rights to a Monte Rosa Therapeutic molecular glue degrader drug in early clinical testing as a potential treatment for autoimmune disorders. The deal comes months after the pharma giant landed rights to an Arvinas targeted protein degrader for cancer.
By: Frank Vinluan
Aliada brings AbbVie an early clinical Alzheimer’s disease drug candidate as well as the platform technology that produced it. Aliada licensed its brain delivery technology from Johnson & Johnson.
By: Frank Vinluan
Crescent Biopharma is going public via a reverse merger with GlycoMimetics that will capitalize the combined company with $200 million. Crescent's lead program is a bispecific antibody for cancer that replicates the properties of a Summit Therapeutics bispecific drug that recently trounced Merck's blockbuster med Keytruda in a pivotal head-to-head study.
By: Frank Vinluan
The FDA had asked Biogen and Sage Therapeutics to provide more clinical data supporting Zurzuvae in major depressive disorder. Citing the time and expense of additional clinical trials, the partners decided against further development in this indication
By: Frank Vinluan
Novo Holdings led the Series A investment in Kivu Biosciences, developer of next-generation antibody drug conjugates for solid tumors. The startup’s ADCs and technology were licensed from Synaffix, a Lonza subsidiary.
By: Frank Vinluan
Novo Nordisk’s Wegovy achieved statistically significant improvement in a Phase 3 study in the fatty liver disease MASH. Based on these preliminary results, the company plans to seek U.S. and European Union approvals in this indication in 2025.
By: Frank Vinluan
Archon Biosciences’ antibody cages change the structure of an antibody to control how a drug distributes in the body. The startup comes from the lab of David Baker, the University of Washington professor of biochemistry recently awarded the Nobel Prize in Chemistry for his work in computational protein design.
By: Frank Vinluan
Archon Biosciences' antibody cages change the structure of an antibody to control how a drug distributes in the body. The startup comes from the lab of David Baker, the University of Washington professor of biochemistry recently awarded the Nobel Prize in Chemistry for his work in computational protein design.
By: Frank Vinluan
Higher doses of a Viking Therapeutics pill that targets two receptors led to greater weight loss without worsening safety or tolerability, according to Phase 1 results presented during the ObesityWeek conference. Meanwhile, an injectable version of this Viking drug is on track to Phase 3 testing.
By: Frank Vinluan
The Novo Nordisk/Ascendis partnership’s lead program is once-monthly injectable semaglutide for type 2 diabetes and obesity. This product candidate will be developed with Ascendis Pharma technology that has already yielded two FDA-approved products with longer dosing intervals.
(833) 317-6278 
